In-vitroandin-vivoevaluation of ciprofloxacin liposomes for pulmonary administration

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial

(2013) David J Serisier et al.   THORAX

Co-spray-dried mannitol–ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

(2010) Handoko Adi et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Formulation andin vitroevaluation of ciprofloxacin containing niosomes for pulmonary delivery

(2010) Esmaeil Moazeni et al.   JOURNAL OF MICROENCAPSULATION

Inhaled drug therapy for treatment of tuberculosis

(2010) Amit Misra et al.   TUBERCULOSIS

Development of a standardized dissolution test method for inhaled pharmaceutical formulations

(2009) Yoen-Ju Son et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Liposomes as delivery systems for antibiotics

(2009) Zuzanna Drulis-Kawa et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

(2009) Harry Heijerman et al.   Journal of Cystic Fibrosis

Platinum, palladium and rhodium release from vehicle exhaust catalysts and road dust exposed to simulated lung fluids

(2008) Claudia Colombo et al.   ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY

Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections

(2007) Sumio Chono et al.   JOURNAL OF CONTROLLED RELEASE